Organ-confined prostate cancer: Treatment with high doses of radioterapy. (Intensity modulated radiotherapy);Cancer de pr_costata órgano-confinado: Tratamiento con altas dosis de radioterapia (radioterapia de intensidad modulada)

Actas Urologicas Espanolas

Volumn 31, Issue 6, 2007, Pages 611-616

  Livi, L ^a   Detti, B ^a   Meattini, M ^a   Sanchez L J ^b   Biti, G P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b AOUC SOD   (Italy)

Author keywords

Intensity modulated radiotherapy treatment; Prostate cancer; Radiotherapy; Rectal toxicity

Indexed keywords

ADENOCARCINOMA; AGED; BLADDER; EVALUATION; FEASIBILITY STUDY; GASTROINTESTINAL DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; METHODOLOGY; MICTURITION DISORDER; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RECTUM; RETROSPECTIVE STUDY; REVIEW;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; RETROSPECTIVE STUDIES; URINARY BLADDER; URINATION DISORDERS;

EID: 34548418188     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(07)73697-5     Document Type: Article

References (28)

1. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002 Aug 1;20(15):3199-3205.
2. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500.
3. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer based on dose comparison and dose response studies. Int. J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):823-832.
4. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 1;18(23):3904-3911.
5. Sandler HM, McLaughlin W, Kish KE, Lichter AS. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995;32:141.
6. Lee, WR, Hanks GE, Hanlon AL, SchultheissTE, Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: futher evidence for a significant dose effect. Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):251-257.
7. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001 Sep;166(3):876-881.
8. Storey MR, Pollack A. Zagars G, Smith L. Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):635-642.
9. Kutcher GJ, Leibel SA, Ling CC, Zelefsky M, Fuks Z. New wine in an old bottle? Dose escalation under dose-volume constraints: a model of conformal therapy of the prostate. Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):415-416.
10. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993 Jul;150(1):110-114.
11. Peeters ST, Heemsbergen WD, van Putten WL. Slot A, Tabak H, Mens JW et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-1034.
12. Emani B, Lyman J, Brown A, Coia L, Goitein M, Munzerider JE et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-122.
13. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:S13-S19.
14. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989 Jun; 16(6):1623-1630.
15. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35.
16. Boehmer D, Bohsung J, Eichwurzel I. Moys A, Budach V. Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer. Radiother Oncol. 2004 Jun:71(3):319-325. Review.
17. Kuban D, Pollack A. Huang E, Levy L, Dong L, Starkschall G et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1260-1268.
18. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1314-1321.
19. Fiorino C. Sanguineti G, Cozzarini C. Fellin G, Foppiano F, Menegotti L et al. Rectal dose-volume constraints in highdose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):953-962.
20. Bucciolini M, Buonamici FB, Casati M. Verification of IMRT fields by film dosimetry. Med Phys. 2004 Jan;31(1): 161-168.
21. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-939.
22. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 1999 May-Jun;5(3): 152-158.
23. Zelefsky MJ, Fuks Z, Wolfe T, Kutcher GJ, Burman C, Ling CC et al. Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy-a dose-escalation study. Radiology. 1998 Oct; 209(1):169-174.
24. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000 Jun;55(3):241-249.
25. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Blol Phys. 2002 Aug 1;53(5):1111-1116.
26. De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):777-787. Review.
27. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/ fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):904-912.
28. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006 Oct;176(4 Pt 1): 1415-1419.